Effect of Target Therapy on Patients Undergoing Synchronic Hepatectomy for Colorectal Liver Metastases
NCT ID: NCT01677728
Last Updated: 2012-09-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
60 participants
OBSERVATIONAL
2007-01-31
2014-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Chemotherapy Alone Versus Chemotherapy Plus Targeted Therapy as Adjuvant Therapy for Initially Unresectable Colorectal Cancer Liver Metastases
NCT06027775
New Adjuvant Chemotherapy of Asymptomatic Resectable Primary Lesion With Unresectable Liver-limited Metastases
NCT01307878
Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence
NCT06120127
Study Comparing HAI Plus Chemotherapy and Chemotherapy Alone in Patients With Unresectable CRLM
NCT03125161
Preoperative Transhepatic Arterial Chemotherapy (TAC) in the Treatment of Liver Metastasis of Resectable Colorectal Cancer
NCT00874406
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Over the past decade, due to the introduction of irinotecan-based or oxaliplatin-based combination chemotherapy, the median survival among patients with colorectal liver metastases (CLM) has increased from 6 \~8 months to more than 20 months5.In recent years, target therapy has rapidly gained attention for the treatment of CLM and is under active investigation.
Although numerous publications have reported the efficacy of target therapy in combination treatment for CLM patients, most of these studies focused solely on those patients without undergoing resection of liver metastases. In contrast, little work has concentrated on exploring the effection of target therapy for CLM patients undergoing Synchronic Hepatectomy.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
arm A
patients received chemotherapy alone
No interventions assigned to this group
arm B
patients received target therapy combined with chemotherapy
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Performance status (ECOG) 0\~1
* colorectal adenocarcinoma pathologically
* without any chemotherapy or radiotherapy
* liver metastases undergoing radical resection
* colorectal cancer undergoing radical resection
* no other metastases
* suitable for chemotherapy
* agreed by patients
Exclusion Criteria
* haven't pathological diagnosis of colorectal adenocarcinoma with liver metastase
* with any chemotherapy or radiotherapy
* with other metastasis
* unresectable colorectal cancer or liver metastases
* unsuitable for chemotherapy or target therapy
* not agreed by patients
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fudan University
OTHER
Xu jianmin
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Xu jianmin
Zhongshan hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Xu Jianmin, MD
Role: STUDY_CHAIR
Shanghai Zhongshan Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Xjianmin
Identifier Type: REGISTRY
Identifier Source: secondary_id
ZSTCC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.